Please login to the form below

Not currently logged in
Email:
Password:

Schering-Plough highlights product pipeline

Global healthcare company Schering-Plough presented its product portfolio to shareholders this week and highlighted several products that are close to market

Global healthcare company Schering-Plough presented its product portfolio to shareholders this week and highlighted several products that are close to market.

The company's chairman and CEO, Fred Hassan, explained how, with nine drugs currently in phase III trials and another three in pre-registration, he believes Schering-Plough currently has one of the best pipelines in the industry and he expects market exclusivity for most key prescription products to continue for several years to come.

Schering-Plough's current portfolio includes an antiplatelet agent Thrombin Receptor Antagonist (TRA), which is currently in phase III trials and has the potential to be a blockbuster.

Simponi, which is licensed to Schering-Plough by Centocor for use in various countries outside the US, is an anti-TNF agent for inflammatory and autoimmune disorders. It is currently under review in the EU for three indications and is in phase III trials in the US for one indication.

Hassan also pointed out that its hepatitis C drug, boceprevir, has proved effective without the side effects, (a rash) of rival medicines.

Dr Thomas P Koestler, executive vice president and president of Schering-Plough Research Institute, said: "Our R&D innovation is visible in our pipeline projects, six of which have been designated 'fast track' by the US Food and Drug Administration (FDA)." He added: "We are pleased that R&D now has the potential to add enormous value to the company's already well-protected marketed product portfolio."

Shareholders were also informed about a range of other medicines in development including two projects for Alzheimer's.

26th November 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics